Objective To determine the percentage of children with nonalcoholic fatty liver disease (NAFLD) in whom intervention for low-density lipoprotein cholesterol or triglycerides was indicated based on National Heart, Lung, and Blood Institute guidelines.
1
The process of atherosclerosis begins in childhood and is associated with dyslipidemia. 2, 3 Therefore, both the American Academy of Pediatrics and the American Heart Association recommend identifying children at risk for premature cardiovascular disease. In 2011, the revised National Heart, Lung, and Blood Institute (NHLBI) Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction 4 reinforced the importance of lipid screening in childhood and provided a pathway for lifestyle and pharmacologic interventions. In addition, they identified subgroups requiring specialized attention but did not address children with nonalcoholic fatty liver disease (NAFLD).
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Body mass index CHILD-1 Cardiovascular Health Integrated Lifestyle Diet LDL-C Low-density lipoprotein cholesterol NAFLD Nonalcoholic fatty liver disease NASH CRN Nonalcoholic Steatohepatitis Clinical Research Network NHLBI National Heart, Lung, and Blood Institute TG Triglycerides NAFLD is an emerging clinical problem in children and adolescents. With an estimated 9.6% prevalence, NAFLD is the most common cause of chronic liver disease in children, 5 and the leading cause of liver transplantation in young adults. [6] [7] [8] Cardiovascular disease is a serious extrahepatic comorbidity in patients with NAFLD, and is the most common cause of death in adults with this condition. [9] [10] [11] In children, NAFLD is also associated with multiple cardiovascular risk factors such as obesity, insulin resistance, hypertension, and dyslipidemia. [12] [13] [14] Recent pediatric NAFLD guidelines include monitoring of lipids. 15 However, the treatment of hypercholesterolemia and/or hypertriglyceridemia in children with NAFLD has not been addressed. Thus, it is unknown how many children with NAFLD require intervention for dyslipidemia. Moreover, there are no longitudinal data on lipids in children with NAFLD in response to intervention. Therefore, the primary study aim was to apply the NHLBI guidelines to children with NAFLD. Specific goals were to determine the frequency of clinical interventions needed for elevated plasma low-density lipoprotein cholesterol (LDL-C) or triglycerides (TG) and the outcomes on lipid profiles after 1 year of dietary standard of care.
Methods
The National Institute of Diabetes and Digestive and Kidney Diseases Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) enrolled children in longitudinal cohort studies (Database and Database 2; NCT01061684) and clinical trials (TONIC; NCT00063635 and CyNCh; NCT01529268). These studies have been described 16, 17 and were performed at each participating pediatric clinical center across the US (Appendix). The studies were approved by the institutional review boards at the participating institutions. Written, informed consent was obtained from a parent or guardian for all participants, and written assent was obtained from children. For this analysis, we included children who were ages 9-18 years of age with biopsy-confirmed NAFLD. Those without weight, height, blood pressure, or fasting lipid panels measured at the initial study visit were excluded from this analysis. Those who were already taking a statin, fibrate, or omega-3 fish oil at the time of enrollment in the study, or those who were subsequently prescribed one of these medications before 48 weeks of followup were excluded from the application of the guidelines as well.
Age and sex were recorded for all participants. The following medical background was obtained for all study participants: presence of diabetes mellitus type I and type II, chronic inflammatory disease (such as juvenile rheumatoid arthritis or lupus), renal disease and dysfunction, HIV status, organ transplant, and the use of any lipid-lowering medications in the preceding 6 months.
Physical measurements included height, weight, systolic and diastolic blood pressures. Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Blood pressure percentiles were computed according to The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. 18 At the initial visit, fasting laboratory assays included total cholesterol, high-density lipoprotein cholesterol, LDL-C, and TG. All laboratory studies were repeated at the 48-week follow-up.
A diagnosis of NAFLD was based on liver histology with ≥5% of hepatocytes containing macrovesicular fat, and exclusion of other causes of liver disease based on clinical history, laboratory studies, and histology. Biopsy specimens were stained with hematoxylin and eosin and Masson's trichrome stains, and reviewed and scored by the Pathology Committee of the NASH CRN according to the NASH CRN scoring system. 19 Liver biopsies were diagnosed as NASH, borderline NASH, or NAFLD without NASH based on the aggregate presence and degree of the individual features of NAFLD. The diagnosis of NASH, borderline NASH, or NAFLD was made as a consensus agreement of the NASH CRN pathology committee.
NHLBI Guidelines
The 2011 revised NHLBI guidelines were applied to our study cohort. Normal plasma lipid levels in children were defined based on The National Cholesterol Education Program (NCEP) Expert Panel on Cholesterol levels in Children. 20 The NHLBI guidelines provide a separate decision tree for LDL-C and TG to determine the specific intervention required, based on the degree of lipid derangement (Figures 1 and 2) . By following the NHLBI algorithms, children who met the thresholds for clinically actionable dyslipidemia were identified at baseline as being in the target LDL-C or the target TG group.
The target LDL-C pathway was applied to those with baseline plasma LDL-C of >130 mg/dL. After receiving dietary counseling, similar to that of the Cardiovascular Health Integrated Lifestyle Diet (CHILD-1) as described in the algorithm (Table III ; available at www.jpeds.com), a repeat fasting lipid profile was obtained at the 1-year follow-up. Taking into consideration the presence of high and moderate risk factors (Table IV; available at www.jpeds.com), combined with the degree to which LDL-C remained elevated, children who did not achieve goal LDL-C would meet criteria for consideration of statin therapy or the intensification of a lipidspecific diet (Table V; available at www.jpeds.com).
The target TG pathway was applied to children with baseline plasma TG with age-specific cutoffs of >100 mg/dL for children <10 years of age, and >130 mg/dL for children 10 years of age and older. In a similar fashion, children received dietary counseling and fasting lipid profiles were obtained at the 1-year follow-up. In children who did not achieve their goal TG, the guidelines provide instructions for initiation of the CHILD 2-TG diet (Table V) or the consideration of pharmacotherapy.
NASH CRN Standard of Care
The NASH CRN Standards of Care Committee developed a uniform set of practices to be applied by investigators in the NASH CRN to the care of pediatric patients with NAFLD. Recommendations for dietary counseling were based on guidelines from the US Department of Agriculture; specifically, limiting the percent of daily caloric intake from saturated fatty acids to <10%, replacing these with monounsaturated and Volume 198 • July 2018 polyunsaturated fatty acids, and limiting dietary cholesterol intake to <300 mg. 21 These recommendations were consistent with those outlined in the CHILD-1 diet in the NHLBI guidelines. However, the individual application of these recommendations and the specifics of caloric and cholesterol intake were not monitored by each participating site.
Statistical Analyses
The demographic and clinical characteristics of all children included in this study were reported using standard descriptive statistics. Medians and ranges were reported for continuous variables and counts and percentages were given for categorical variables. 
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Following the NHLBI guidelines for the management of dyslipidemia in children, we calculated the frequency of actionable cases as patients flowed through the NHLBI branchtree algorithm. Two separate algorithms were used to define dyslipidemia targeting LDL-C and TG levels independently. Subjects already on statins, fibrates, or omega-3 fish oil were excluded from analysis.
Study participants were pooled from 4 distinct NASH CRN protocols. Sensitivity analyses were performed to determine whether lipid levels at enrollment or follow-up varied between protocols. R version 3.3.2 software (The R Foundation for Statistical Computing, Vienna, Austria) was used for all analyses.
Results
There were 669 children enrolled in the NASH CRN, of whom 3 were excluded for missing data, 3 were excluded because they did not have NAFLD, and 40 were excluded because they were <9 years of age. Thus, 623 children with NAFLD ages 9-18 years were evaluated in this study; 25 were receiving pharmacologic intervention (statin, n = 10; fish oil, n = 15). During the course of the investigation, before the week 48 evaluation, an additional 13 children were prescribed antihyperlipidemic medications (statin, n = 6; fish oil, n = 7). Therefore, there were 585 children with NAFLD not taking antihyperlipidemic medications evaluated for their response to standard of care intervention at both baseline and 48 weeks. Demographic and clinical characteristics for these 585 children are shown in Tables I and II. There was a male predominance of 72% (n = 419) in our group. The mean age for all subjects was 12.8 years (SD, 2.4), and a BMI of 32.6 kg/m 2 (SD, 6.5). In the cohort, the median LDL-C was 97 mg/dL (range, , and the median TG concentration was 133 mg/dL (range, 18-726). Using the NHLBI guidelines, 4% of participants (n = 24) met criteria for the target LDL-C pathway alone and 41% (n = 239) met criteria for the TG pathway alone. An additional 10% of participants (n = 60) had lipid profiles that qualified them for both target pathways. The remaining 45% (n = 262) did not qualify for either pathway.
LDL Cholesterol
As shown in Figure 1 , 14% (n = 84) of our study participants had levels that met criteria for intervention in the target LDL-C pathway. The median LDL-C of those targeted was 145 mg/dL (range, 131-212). After 1 year, fasting lipid panels were available for 78 participants with targeted LDL-C. Of these, 51% (n = 40) achieved goal levels as shown in An additional 27% of participants (n = 21) with targeted LDL-C met criteria for enhanced dietary modifications with a lipid-specific diet (Figure 1, B) . As shown in Figure 1 , application of the guidelines including risk factors (as shown in supplemental data) shows that 22% (n = 17) of those originally (29) 18 (30) 57 (22) 152 (26) ALT, Alanine aminotransferase; AST, aspartate aminotransferase; DBP, diastolic blood pressure; GGT, gamma-glutamyl transferase; SBP, systolic blood pressure. Values are n (%), median (range), or median ± SD. *Per the NHLBI algorithm, participants with TG >500 mg/dL were referred automatically to a lipid specialist for pharmacologic intervention and were, therefore, not included in the analysis of participants receiving dietary intervention and repeat fasting lipid panels. with targeted LDL-C met criteria for statin at 1 year. Thus, the combination of children already taking a statin at baseline or reaching criteria for initiation of a statin at 1 year represented 5.3% (33 of 623) of the entire cohort.
Triglycerides
As shown in Figure 2 , 51% of the cohort (n = 299) met the criteria for intervention in the target TG pathway. The median TG concentration of those targeted was 138 mg/dL (range, 38-330) in children <10 years of age and 147 mg/dL (range, 20-727) for those 10-18 years of age. Three participants (0.5%) had baseline TG concentrations that warranted referral to a lipid specialist as shown in Figure 2 , A. After 1 year, fasting lipid panels were available for 289 participants with targeted TG. Of these, 25% (n = 73) achieved goal TG levels as shown in Figure 2 , B. Achieving goal TG at the 1-year follow-up was associated with a significantly greater decrease in BMI Z-score compared with those who did not achieve goal levels of TG ( 
Lipid Values and Histology
As shown in Table I , there was no significant difference in meeting criteria for target LDL-C, TG, both, or neither by fibrosis stage (P = .098) or diagnosis of NASH (P = .334).
Sensitivity Analysis
In both sets of sensitivity analyses, the percent of participants from each of the 4 studies meeting criteria for application of the LDL and TG algorithms was not statistically significant (P = .094 and P = .341, respectively). Furthermore, comparison between the 4 groups and the percentages of those achieving various LDL and TG-related outcomes also did not differ statistically (P = .484 and P = .787, respectively).
Discussion
We studied the prevalence of clinically relevant lipid derangement in a large, multicenter cohort of children with NAFLD from pediatric centers across the US. Two-thirds of the cohort met criteria for intervention based on either LDL-C or TG elevation. Abnormalities in TG concentration was the more common lipid derangement. After 1 year of care, approximately one-half of children in the target LDL-C group and onefourth of children in the target TG group reached the recommended lipid level as per the NHLBI guidelines. Thus, a substantial number of participants, despite receiving standard of care recommendations, met the criteria for additional therapeutic intervention in the form of nutrition and/or medication. Approximately 30% of children in the target LDL-C group and 40% of children in the target TG group met thresholds for a lipid-specific CHILD-2 diet and continued lipid monitoring. Furthermore, one-fifth of the cohort with targeted LDL-C and close to 40% of participants with targeted TG met criteria for consideration of antihyperlipidemic medications.
In children with NAFLD, there is a higher prevalence of clinically actionable dyslipidemia than in the general population. Based on data from NHANES 1999-2012, 6.5% of adolescents aged 12-17 years in the general population met target LDL-C values compared with 15% of our cohort of children with NAFLD. 22 Notably, our study included longitudinal data and demonstrated that 5.3% of the children with NAFLD in our cohort were either already prescribed or reached criteria for use of a statin at follow-up. There are no available longitudinal data for comparison. However, using crosssectional data only, indications for statin use were met in <1% of adolescents ages 12-17 years and ≥2.5% of youths 17-21 years in the general population. 23 Furthermore, the prevalence of hypertriglyceridemia meeting target TG levels is 12% in the general population 24 and 25% in children with obesity. 25, 26 Thus, the fact that 51% of our cohort of children with NAFLD had target TG levels necessitating intervention and indicates the clinical relevance of dyslipidemia in pediatric NAFLD. Based on these findings, lipid screening is warranted in all children with NAFLD.
Children with NAFLD and dyslipidemia should be considered to be at increased risk for premature cardiovascular disease. The association between NAFLD and dyslipidemia in children has been shown to be strong and independent of weight. 13, 27 In NAFLD, the predominant pattern observed is combined dyslipidemia; characterized by an elevation in LDL-C, TG, and a decrease in high-density lipoprotein cholesterol. 28 Combined dyslipidemia is highly atherogenic and predictive of future cardiovascular disease. 29, 30 Notably, atherosclerosis is a progressive process that begins in childhood 31, 32 and is associated with dyslipidemia. 33, 34 In addition to dyslipidemia, NAFLD itself may increase the risk of atherosclerosis. In an autopsy study of children ages 2-19 years the prevalence of atherosclerosis was increased by a factor of 2 in those children with NAFLD. 35 In children with NAFLD, carotid intimal media thickness has been shown to be greater than in matched controls, namely, children with obesity but without NAFLD. [36] [37] [38] Therefore, although coronary artery disease and stroke tend to be conditions of later adulthood, this evidence suggests that children with NAFLD may be at an increased risk of cardiovascular morbidity and mortality, perhaps at a younger age than the general population. Screening for dyslipidemia in childhood, as recommended by the NHLBI guidelines, allows for both early detection of cardiovascular disease risk and the potential for intervention.
The management of dyslipidemia in children is rooted in nutritional intervention. In a randomized controlled, multicenter trial of children with dyslipidemia, the Dietary Intervention Study in Children (DISC), dietary counseling by a registered nutritionist produced a significant decrease in the intake of saturated fats and cholesterol. This change resulted in a decrease in the plasma LDL-C compared with those who received routine educational materials on heart healthy diet. These findings were sustained over 3 years. 39 In the present study, the initiation of a CHILD-2 TG or LDL-C specific diet was the most common intervention required. With standard of care dietary recommendations, one-half of the targeted LDL-C cohort and one-fourth of the targeted TG cohort achieved their lipid goals at the 1-year follow-up. However, a substantial percentage of those with targeted lipid levels met criteria for ongoing nutritional intervention. Although it was not known how many children had their counseling done by a physician versus a registered dietician, prior studies have shown that dietary education from a registered dietician can be more effective for long-term LDL-C reduction. 40 Nonetheless, pediatric gastroenterologists have identified inadequate access to registered dieticians and lack of insurance coverage for such referrals as substantial barriers to care. 41 Therefore, strong consideration should be given to making access to a registered dietician a standard part of care in children with NAFLD.
Statins are the mainstay of therapy for individuals in whom dietary interventions fail to achieve goal LDL-C levels and should also be considered for cardiovascular risk reduction, even in patients with NAFLD. However, given their potential adverse effect profile, these medications are often underused. It is known that statins may cause increases in serum aminotransferases, 42 and are, thus, often avoided in patients with elevated aminotransferases or preexisting liver disease. The American Association for the Study of Liver Diseases practice guidelines concluded that in adults "statins are safe in patients with liver disease and there is no evidence that patients with chronic liver disease including NAFLD and NASH are at higher risk for serious liver injury than those without liver disease." 43 In children, the prevailing data on the efficacy and safety of statin use has been in the population with familial hypercholesterolemia. In a meta-analysis of these studies, statins were shown to be efficacious for lipid lowering and were not associated with an increased risk of liver-related adverse events. 44 However, there is a gap in knowledge regarding efficacy and safety in children with underlying liver disease, such as NAFLD. Although the NHLBI guidelines recommend their use in adverse lipid profiles refractory to diet and lifestyle changes, additional studies on the long-term benefits and safety of statins in children with NAFLD would be beneficial.
A strength of this study includes the large, multicenter cohort that was broadly representative of children with clinical NAFLD. Subjects were recruited by the NASH CRN, which has geographic diversity as well as a detailed, rigorous protocol to phenotype the cohort. Furthermore, the longitudinal nature of this study adds novel information about the treatment of hypercholesterolemia and hypertriglyceridemia in children with NAFLD, including how interventions such as dietary modifications influence this over time. Our study had excellent retention at 48 weeks of follow-up.
A limitation of this study is that, although recommendations in the standard of care documents on daily caloric intake from saturated fatty acids and cholesterol were similar to those in the NHLBI guidelines, they were not identical. Furthermore, the individual counseling provided by physicians versus registered dieticians at study sites was not monitored, and specific recommendations were undocumented. Although all participants received some form of dietary counseling, it is possible that there may be variation between study sites in terms of specific counseling that was offered. Although a lack of rigid control in the dietary implementation limited the homogeneity of response, the implementation across centers is more reflective of the real world and, thus, is likely to be a more generalizable result with respect to the rates of change in this patient population. Additionally, we may have underestimated children with hypercholesterolemia who would meet criteria for consideration of medication, based on incomplete family history of cardiovascular disease. Last, our study evaluated children ages 9-18, because this is the recommended age for universal screening of lipids, per the NHLBI guidelines. However, this highlights a gap in the knowledge about the cardiovascular risk in younger children with NAFLD, and future studies are needed to better evaluate this age group.
In summary, NAFLD is a common clinical problem that is frequently associated with clinically actionable dyslipidemia. Targeted dietary interventions can be effective for a subset of this population. The number of children who will require more aggressive intervention including medications is substantial. This finding strongly supports the new pediatric NAFLD guidelines 15 and merits consideration of pediatric NAFLD as a risk factor for clinically significant dyslipidemia in future pediatric lipid guidelines. Future studies should prospectively address safety of statin use specifically in children with NAFLD and identify optimal levels of LDL-C and TG to reduce cardiovascular disease risk in children with NAFLD. ■ Submitted for publication Nov 30, 2017 ; last revision received Jan 19, 2018; accepted Feb 14, 2018 
